Amgen (AMGN) Share-based Compensation Growth (3y) (2012 - 2026)
Amgen (AMGN) Share-based Compensation Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 6.23% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.48% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 20.81% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 11.51% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 5.27% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 18.94% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.51% |
| Mar 31, 2026 | 16.86% |
| Dec 31, 2018 | 47.49% |
| Sep 30, 2018 | -30.96% |
| Jun 30, 2018 | 1.10% |
| Mar 31, 2018 | -8.29% |
| Dec 31, 2017 | 11.71% |
| Sep 30, 2017 | -5.11% |
| Jun 30, 2017 | -5.01% |
| Mar 31, 2017 | -11.65% |
| Dec 31, 2016 | -3.49% |
| Sep 30, 2016 | -6.02% |
| Jun 30, 2016 | -8.07% |
| Mar 31, 2016 | -17.32% |
| Dec 31, 2015 | -40.80% |
| Sep 30, 2015 | 37.00% |
| Jun 30, 2015 | -5.01% |
| Mar 31, 2015 | -2.27% |
| Dec 31, 2014 | -40.98% |
| Sep 30, 2014 | 13.20% |